Send to

Choose Destination
See comment in PubMed Commons below
J Pediatr Pharmacol Ther. 2013 Oct;18(4):292-7. doi: 10.5863/1551-6776-18.4.292.

Evaluation of monitoring for metabolic effects in children treated with second generation antipsychotics in a pediatric clinic.

Author information

  • 1Department of Pharmacy, Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Tulsa, Oklahoma ; Department of Pediatrics, The University of Oklahoma College of Medicine, Tulsa, Oklahoma.
  • 2Department of Pharmacy, University of Louisville Hospital, Louisville, Kentucky.
  • 3Department of Pharmacy, Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Tulsa, Oklahoma.



The aim of this retrospective study was to identify the frequency of recommended metabolic monitoring and follow-up in pediatric patients on second-generation antipsychotic (SGA) medications from a pediatric clinic.


A retrospective review of electronic medical records of all patients on antipsychotics from an academic medical center pediatric clinic was conducted. Inclusion criteria required patients to be established members of the pediatric clinic, < 19 years of age, and on ≥ 1 SGA for at least 1 year, regardless of medical diagnosis. Data collection consisted of patient demographic information and frequency of family history, vital signs, and recommended laboratory monitoring.


A total of 67 patients on antipsychotics were identified. After the application of inclusion criteria, 32 patients qualified for review. The average age was 13.5 ± 4 years and gender distribution included 72% males. Only 4 (13%) patients had documented baseline monitoring that included weight, blood pressure, and fasting lipid panel. No patient had a fasting plasma glucose recorded at any point during antipsychotic therapy. Follow-up monitoring decreased over time, with the exception of quarterly weight and annual blood pressure.


The results of this study highlight the lack of baseline and periodic monitoring that occur when pediatric patients are prescribed antipsychotic medications, putting the patient at risk for adverse events. The marked increase in antipsychotic prescribing and concerns related to their safety emphasize the need for improvement in monitoring of antipsychotic medications. This gap in patient care and safety opens an excellent opportunity for a clinical pharmacy team to provide education and assistance with SGA monitoring for the purpose of providing optimal patient care.


antipsychotics; children; clinic; monitoring

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk